Clinical trial
A Phase I Dose Escalation Study on the Tolerability and Activity of TriN 2755 in Patients With Advanced Solid Tumors and Sarcomas Using Two Different Dosage Regimens
NCT01259518 is registered in ClinicalTrials.gov with Trin Therapeutics GmbH as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Dose Escalation Study on the Tolerability and Activity of TriN 2755 in Patients With Advanced Solid Tumors and Sarcomas Using Two Different Dosage Regimens
- Lead sponsor
- Trin Therapeutics GmbH
- Phase
- Phase 1
- Overall status
- Unknown status
- Start date
- November 30, 2009
- Completion date
- January 31, 2012
- Enrollment
- 48 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.